19:38 , Apr 27, 2018 |  BC Week In Review  |  Company News

Tonghua gets rights to two insulin products from Adocia

Adocia S.A. (Euronext:ADOC) granted Tonghua Dongbao Pharmaceutical Co. Ltd. (Shanghai:600867) exclusive rights to develop and commercialize BioChaperone Lispro (BioChaperone Ultra fast-acting insulin analog) and BioChaperone insulin combo in China and other undisclosed countries. Adocia will receive...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Phase Ib started

Adocia began a double-blind, double-dummy, 3-way crossover, German Phase Ib trial of subcutaneous BioChaperone Combo given before a meal on 3 consecutive days in 36 patients. The trial will compare BioChaperone Combo vs. subcutaneous ...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Phase Ib started

Adocia began a double-blind, crossover, German Phase Ib trial to compare BioChaperone Combo to Humalog Mix25 given at the beginning of a standardized mixed meal in about 28 patients. In 2013, Adocia and Eli...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Phase Ib started

Adocia began a double-blind, crossover, German Phase Ib trial to compare 0.8 IU/kg Biochaperone Combo to 0.8 IU/kg Humalog Mix25 and 0.2 IU/kg Humalog insulin lispro plus 0.6 IU/kg Lantus insulin glargine in...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Final Phase I/II data

Final data from a double-blind, crossover, German Phase I/II trial in 20 Type I diabetics showed that a single 0.8 IU/kg dose of BioChaperone Combo had a faster onset of action, defined as time to...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Preliminary Phase I/II data

Preliminary data from a double-blind, crossover, German Phase I/II trial in 20 Type I diabetics showed that 0.8 IU/kg BioChaperone insulin combo had a 30% faster onset of action, defined as time to >=5% reduction...
08:00 , Mar 3, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Anika Therapeutics Inc. (NASDAQ:ANIK) rose $11.43 (33%) to $45.90 on Wednesday after saying FDA approved Monovisc to treat osteoarthritis of the knee. Monovisc is a single injection that delivers hyaluronic acid from a non-animal...
01:51 , Feb 28, 2014 |  BC Extra  |  Clinical News

Adocia jumps on Phase I/II diabetes data

Adocia S.A. (Euronext:ADOC) jumped EUR 2.38 (18%) to EUR 15.30 on Thursday after reporting preliminary data from a Phase I/II trial evaluating its BioChaperone insulin combo to treat Type I diabetes. In 20 diabetics, 0.8...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Phase I/II started

Adocia began a double-blind, crossover, German Phase I/II trial to compare a version of Lantus insulin glargine that uses Adocia's BioChaperone polymer technology in combination with Humalog insulin lispro vs. Humalog Mix insulin...